|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1ST TIME HERE?.....CLICK THE FLASHING RED BUTTON ON THE LEFT! | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
May 05, 2006
National Multiple Sclerosis Society Webcast: CLICK HERE
"The first webcast in a two-part series on current research into MS treatments. Our presenter is John Richert, MD, the Society’s Vice President of Research and Clinical Programs. Dr. Richert will discuss the drug Tysabri, as well as the progress of several MS therapies undergoing clinical trials, including: • Retuximab for primary-progressive MS • Combination Therapy with Avonex and Copaxone for relapsing-remitting MS • Oral Therapies Fingolimod, Fumarate, Temsirolimus, and Pirfenidone |